Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $5.6 million.

  • Beam Therapeutics' Depreciation & Amortization (CF) rose 155.25% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year increase of 103.0%. This contributed to the annual value of $21.9 million for FY2024, which is 955.93% up from last year.
  • As of Q3 2025, Beam Therapeutics' Depreciation & Amortization (CF) stood at $5.6 million, which was up 155.25% from $5.5 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $5.6 million for Q2 2024, and its period low was $1.4 million during Q1 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $4.8 million (2023), whereas its average is $4.2 million.
  • Per our database at Business Quant, Beam Therapeutics' Depreciation & Amortization (CF) soared by 13690.99% in 2022 and then plummeted by 68.15% in 2025.
  • Over the past 5 years, Beam Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $2.6 million in 2021, then soared by 49.73% to $3.9 million in 2022, then surged by 35.95% to $5.4 million in 2023, then increased by 1.51% to $5.4 million in 2024, then grew by 2.15% to $5.6 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $5.6 million for Q3 2025, versus $5.5 million for Q2 2025 and $5.5 million for Q1 2025.